← Oncology Approval Tracker

FDA DECISION ·

Ivra

melphalan hydrochloride · Apotex

FDA approvalNew formulationMultiple myeloma
Open LinkedIn brief ↓

1 min read · estimated

Sources

APPROVED USE

What FDA approved

An IV melphalan presentation for palliative treatment of multiple myeloma in patients for whom oral therapy is unsuitable.

LAMPGEN ANALYSIS

Why it matters

This approval adds a parenteral presentation for a defined palliative myeloma use.

What research teams should watch

Record the route and treatment intent to distinguish this product's label from transplant-conditioning and liver-directed melphalan uses.

PRIMARY RECORDS

Sources